AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX)

CUSIP: 037326105

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / Common Stock, par value $0.00001 per share
Shares outstanding
37,347,828
Total 13F shares
20,391,503
Share change
+459,392
Total reported value
$417,920,110
Price per share
$20.49
Number of holders
51
Value change
+$9,592,150
Number of buys
31
Number of sells
12

Quarterly Holders Quick Answers

What is CUSIP 037326105?
CUSIP 037326105 identifies ANTX - AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) as of Q4 2023

As of 31 Dec 2023, AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) was held by 51 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 20,391,503 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, LLC, BVF INC/IL, CITADEL ADVISORS LLC, Frazier Life Sciences Management, L.P., JANUS HENDERSON GROUP PLC, Avidity Partners Management LP, VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., and Octagon Capital Advisors LP. This page lists 51 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.